Tiziana Life Sciences Ltd — Company profile
Healthcare · Biotechnology · United Kingdom
Last price 0.8 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 102.42M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer’s disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases. The company is headquartered in London, the United Kingdom.
Details
| Name | Tiziana Life Sciences Ltd |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 10 |
| Founded | 2013 |
| Ipo Date | 2000-03-24 |
| Ceo | Ivor Elrifi |
| Country | United Kingdom |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | BMG889121031 |
| Cusip | G88912103 |
| Cik | 0001723069 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Dr. Ivor R. Elrifi Ph.D. | Chief Executive Officer and Executive Director |
| Gabriele Marco Antonio Cerrone M.B.A. | Founder and Executive Chairman |
| Keeren Shah | Chief Operating Officer and Chief Financial Officer |
| William Edward Tente M.S. | Chief Regulatory Officer |
| Dr. Richard K. Kim M.D. | Chief Medical Officer |
| Dr. Napoleone Ferrara M.D. | Member of Scientific Advisory Board |
Contact
| Address | 14/15 Conduit Street, London, W1S 2XJ, United Kingdom |
| Phone | 44 20 7495 2379 |
| Website | https://www.tizianalifesciences.com |